Chemoimmunkonjugat (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Chemoimmunkonjugat" in German language version.

refsWebsite

Global rank German rank

19nih.gov

4^th place

7^th place

5aacrjournals.org

8,869^th place

5,334^th place

1ascopubs.org

low place

1doi.org

2^nd place

3^rd place

aacrjournals.org

cancerres.aacrjournals.org

D. A. Johnson und B. C. Laguzza: Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. In: Cancer Research 47, 1987, S. 3118–3122. PMID 3495327
W. C. Shen u. a.: Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. In: Cancer Research 46, 1986, S. 3912–3916. PMID 2873883
R. O. Dillman u. a.: Superiority of an acid-labile daunorubicinmonoclonal antibody immunoconjugate compared to free drug. In: Cancer Research 48, 1988, S. 6097–6102. PMID 3262420
H. K. Erikson: Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing. In: Cancer Res 66, 2006, S. 4426–4433. PMID 16618769

mct.aacrjournals.org

L. M. Smith u. a.: Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. In: Molecular Cancer Therapeutics 5, 2006, S. 1474–1482. PMID 16818506

ascopubs.org

jco.ascopubs.org

A. W. Tolcher u. a.: Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. In: Journal of Clinical Oncology 21, 2003, S. 211–222. PMID 12525512

doi.org

Stephen Parmley: Resurrecting a magic bullet. In: Science-Business eXchange. 7, 2014, doi:10.1038/scibx.2014.1397.

nih.gov

ncbi.nlm.nih.gov

S. Jaracz u. a.: Recent advances in tumor-targeting anticancer drug conjugates. In: Bioorganic & Medicinal Chemistry 13, 2005, S. 5043–5054. PMID 15955702 (Review)
J. R. Johnson u. a.: A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro. In: British Journal of Cancer 44, 1981, S. 472–475. PMID 7284242
D. Scharma u. a.: Antibody targeted drugs as cancer therapeutics. In: Nature Reviews Drug Discovery 5, 2006, S. 147–159. PMID 16424916 (Review)
M. C. Garnett: Targeted drug conjugates: principles and progress. In: Advanced Drug Delivery Reviews 53, 2001, S. 171–216. PMID 11731026 (Review)
F. R. Maxfield und T. E. McGraw: Endocytic recycling. In: Nature Reviews Molecular Cell Biology 5, 2004, S. 121–132. PMID 15040445 (Review)
V. Guillemard und S. H. Uri: Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and targetdependent selectivity. In: Oncogene 23, 2004, S. 3613–3621. PMID 15034547
S. O. Doronina u. a.: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. In: Nature Biotechnology 21, 2003, S. 778–784. PMID 12778055
L. M. Smith u. a.: Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97. In: Molecular Cancer Therapeutics 5, 2006, S. 1474–1482. PMID 16818506
R. Haag und F. Kratz: Polymer therapeutics: concepts and applications. In: Angewandte Chemie Internationale Edition 45, 2006, S. 1198–1215. PMID 16444775
I. Ojima: Guided molecular missiles for tumor-targeting chemotherapy - case studies using the second-generation taxoids as warheads. In: Accounts of Chemical Research 41, 2008, S. 108–119. PMID 17663526 (Review)
D. A. Johnson und B. C. Laguzza: Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. In: Cancer Research 47, 1987, S. 3118–3122. PMID 3495327
W. C. Shen u. a.: Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells. In: Cancer Research 46, 1986, S. 3912–3916. PMID 2873883
R. O. Dillman u. a.: Superiority of an acid-labile daunorubicinmonoclonal antibody immunoconjugate compared to free drug. In: Cancer Research 48, 1988, S. 6097–6102. PMID 3262420
C. Wängler u. a.: Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity. In: Bioconjug Chem 19, 2008, S. 813–820. PMID 1836151
C. Wängler u. a.: Improved syntheses and applicability of different DOTA building blocks for multiply derivatized scaffolds. In: Bioorganic & Medicinal Chemistry 16, 2008, S. 2606–2616. PMID 18065226
L. D. Apelgren u. a.: Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs. In: Bioconjug Chem 4, 1993, S. 121–126. PMID 7873643
H. K. Erikson: Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing. In: Cancer Res 66, 2006, S. 4426–4433. PMID 16618769
A. W. Tolcher u. a.: Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. In: Journal of Clinical Oncology 21, 2003, S. 211–222. PMID 12525512
Y. F. Huang u. a.: Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. In: ChemBioChem 10, 2009, S. 862–868. PMID 19253922